BSD Medical Corporation (NASDAQ:BSDM) today announced that hyperthermia in conjunction with particle therapy was highlighted at the annual meeting of the German Society of Radiation Oncology (DEGRO), which was recently held in Magdeburg, Germany. A total of 2,500 scientists and radiation oncologists attended the meeting.
Hyperthermia in combination with particle therapy (hadron therapy) was highlighted in a symposium titled "Hadrontherapy and Hyperthermia," which was chaired by Jürgen Debus MD PhD, chairman of Radiation Oncology at the University Medical School of Heidelberg and CEO of HIT Heidelberg Ionbeam Therapycenter, and Eugen Hug MD, Director of the Proton Therapy Center of Paul Scherrer Institute at Villigen, Aargau, Switzerland.
Dr. Debus stated that UMS Heidelberg plans to conduct research on the use of hyperthermia and particle therapy, using both protons and heavy ions, at its state-of-the-art HIT Heidelberg Ionbeam Therapycenter, thus taking advantage of the strong rationale for combining hyperthermia with particle therapy. UMS Heidelberg has operated the HIT Heidelberg Ionbeam Therapycenter, which was contracted from Siemens Healthcare, since 2009. Particle therapy is an innovative form of radiation treatment that can deliver a higher targeted dose of radiation to the tumor while preserving surrounding tissue.
Stefan Bodis MD, chairman of radiation oncology at Kantonsspital Aarau, Switzerland, presented the clinical treatment projects for the newly installed BSD-2000 3D Hyperthermia System at their institution. Dr. Bodis reported that they are using hyperthermia in combination with particle therapy using protons for the treatment of deep seated tumors, including soft tissue sarcomas and pancreas cancer, in cooperation with the Proton Therapy Center of the PSI Paul Scherrer Institute.
Oliver Ott MD, University Medical School of Erlangen, Germany, presented an invited lecture highlighting the clinical results of hyperthermia in combination with radiation for the treatment of chest wall recurrence, bladder, and cervical cancer. Dr. Ott stated that hyperthermia and radiation therapy are routinely used to treat these patients. The Department of Radiation Oncology of UMS Erlangen operates a clinical hyperthermia unit that includes three dedicated hyperthermia treatment systems: the BSD-500 Hyperthermia System, the BSD-2000 3D Hyperthermia System, and the BSD-2000-3D MR Hyperthermia System. The striking advantages of image guided hyperthermia therapy were highlighted in the presentation.
New cancer projections show increased prostate cases by 25% in 2050, despite prevention efforts